MorphoSys AG

General information
MorphoSys AG
Semmelweisstr. 7
82152 Planegg, Bavaria

Contact person: Jean-Paul Kress, Chief Executive Officer
Company main phone: +49 (89) 899270
Company main fax:  +49 (89) 89927222
Year founded:1992
Source of foundation:Independent foundation
Name of foundation source:Founded by Dr. Simon Moroney and Prof. Dr. Andreas Pl├╝ckthun
No. of employees: Worldwide:  464
Corporate description / mission:
MorphoSys is a global biopharmaceutical company with a high-level focus on the development of innovative medicines, primarily in the oncology sector. The company's main offerings include the research, development, and delivery of therapies aimed at treating difficult-to-treat and debilitating types of cancer. MorphoSys primarily serves the healthcare and pharmaceutical industries.
State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 1999
Remarks on ownership / listings
MorphoSys is headquartered in Planegg, Germany, and has its U.S. operations anchored in Boston, Massachusetts.
  • Biotechnology - Therapeutics and Diagnostics
  • Antibodies
  • Immunotherapy
  • Small molecules
Primary therapeutic areas:
  • Cardiovascular / cardiology
  • Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
  • Diseases of the eye / ophthalmology
  • Endocrine, nutritional and metabolic diseases / endocrinology
  • Musculoskeletal system and connective tissue / Orthopedics
  • Neoplasms / cancer / oncology
  • Respiratory / pulmonology
  • Skin and subcutaneous tissue / dermatology
Business model:
  • Manufacturer
  • Out-licensing
  • R&D
  • Supplier / Distributor
Customer segments:
  • Hospitals
  • Large biotech & big pharma
  • Physicians / doctors
  • Small biotech
  • Direct (own sales force)
Summary Products / Services / Technologies
Number of Biotech Products
Phase I:1
Phase II:6
Phase III:4
On the market:1
Description of products:
Pelabresib, etc.
Special IP situation:
MorphoSys has built a strong IP portfolio around its proprietary technology, HuCAL.
Technology used:
HuCAL (Human Combinatorial Antibody Library) technology
Financing details
Fiscal year (end of) 2023
Revenues:USD 257.82M
R&D expenses:USD 306.87M
Cash:USD 171.50M
Total liabilities:USD 2'139.40M
No. of shares:37'716'400
Market cap. / valuation:USD 2'721.32M
Collaborations & Clients
Partnering strategy / collaborations:
Ultragenyx and Mereo Biopharma etc